Artemisinin
- 803.603
- +1.376+0.17%
How promising is the vitamins bull market? Zhejiang Nhu's Q2 net profit of 1.335 billion yuan reached a new high|Interpretation of financial report.
① Vitamins have significantly boosted manufacturers' performance in the bull market; ② Q2 net profit of Zhejiang Nhu reached a new high compared to the same period in history; ③ The company benefits from a high proportion of overseas business; ④ The Q3 increase has widened, further benefiting manufacturers.
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
Shanghai Fosun Pharmaceutical Reports 1H Results
Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China; Triggers $2M Milestone Payment To Ardelyx Under The Terms Of The License Agreement Between Co And Shanghai Fosun Pharmaceutical Industrial Development Co.
Market Chatter: Fosun Pharma in Talks With Beijing Over Pfizer-BioNTech's COVID-19 Vaccine; Shares Fall 4%
Shanghai Fosun Pharmaceutical reports FY results
Fosun Pharma Forms Two Funds to Invest in New Drug-Related Projects
Fosun Pharma Unit to Pay $127 Million for 70% Stake in Chinese Medical Institution
Baiyunshan Pharmaceutical's Q3 Profit Jumps 10%
Fosun Pharma Buys Majority Stake in Vaccine Maker; Shares Slide 4%
Fosun Pharma, Three Others Form Investment Partnership
Sector Update: Health Care Stocks Relatively Flat Premarket Friday
Genetron Health Working With Jiangsu Fosun Pharmaceuticals to Commercialize Molecular Cancer Test in China
Genetron Health And Fosun Pharma Announce Exclusive Partnership To Commercialize Seq-MRD In China; Financial Details Not Disclosed
Ligand Pharmaceuticals Collaborates With China Resources Double-Crane to Develop Oral COVID-19 Therapeutic
Ligand Pharmaceuticals and China Resources Double-Crane ink collaboration agreement
Fosun Pharma Setting Up Children-Focused Medical Services JV in Chinese City; Shares Slide 3%
BRIEF-BlackRock Inc's Long Position In Fosun Pharma Rises To 6.39% - HKEX Filing
BUZZ-HK-listed WuXi Biologics leads slide in pharma stocks on Merck COVID-19 pill success